Who is sponsoring NCT06608940?

NCT06608940 is sponsored by Case Comprehensive Cancer Center.

What condition does NCT06608940 study?

NCT06608940 studies Hepato Cellular Carcinoma (HCC).

What drugs are being tested in NCT06608940?

Interventions: BC3402, Durvalumab, Tremelimumab.

What is the status of NCT06608940?

NCT06608940 is currently WITHDRAWN.

Last reviewed 2026-02-17 · How we verify

A Phase Ib/II Study of BC3402, a Novel Anti-TIM3 Agent, in Combination With Tremelimumab Plus Durvalumab (STRIDE) in Advanced, Unresectable Hepatocellular Carcinoma

NCT06608940 Phase 1/Phase 2 WITHDRAWN

The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S. Food and Drug Administration (FDA).

Details

Lead sponsor	Case Comprehensive Cancer Center
Phase	Phase 1/Phase 2
Status	WITHDRAWN
Start date	2025-11
Completion	2028-01-01

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

BC3402
Durvalumab
Tremelimumab

Primary outcomes

Overall response rate(ORR) per RECIST v1.1 — From registration up to 2 years post end of treatment(EOT) or study closure
The ORR rate and 95% CI will be calculated.

Countries

United States